# Junta clínica — PT-pseudo_b63dfe0f311e (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_b63dfe0f311e",
  "pid": "PT-pseudo_b63dfe0f311e",
  "task": 1,
  "psa": 5.3,
  "age": 67,
  "months": 2,
  "pirads": "2",
  "psad": 0.1,
  "psav": 0.47,
  "psap": 5.1,
  "vol": 50.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.39097,
  "medhx": "Hypertension, Hypercholesterolaemia",
  "meds": "amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, rosuvastatin",
  "notes": "PSA 5.3 ng/mL. PI-RADS 2. PSAD 0.10. Prostate volume 50 mL. csPCa 0.39.",
  "pmhx": [
    "Hypertension",
    "Hypercholesterolaemia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "68 kg",
    "height": "175 cm",
    "bmi": "22.2",
    "bp": "138/89 mmHg",
    "hr": "85 bpm",
    "smoking": "Ex-smoker (37 pack-yr, quit 2018)",
    "last_dental": "2 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "17 Feb 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ongoing evaluation of elevated prostate-specific antigen levels alongside reassessment after a previous biopsy."
    },
    {
      "s": "History",
      "t": "First noted for a PSA rise in late 2022, this 67-year-old widower has since been tracked by his primary care physician. He works as a retired carpenter residing in an independent retirement community, with his sister designated as next of kin. A 37 pack-year smoking history ends in 2018. Clinical background includes hypertension and hypercholesterolaemia, currently treated with amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, and rosuvastatin. He avoids alcohol entirely, swims weekly, and manages mild knee pain stemming from years of manual labour. A cardiology assessment in autumn 2024 confirmed stable cardiovascular health. Urinary symptoms remain minimal, anchored at a baseline IPSS of 9, and he commutes 60 minutes by train for each clinic visit. The clinical picture aligns with a positive prior biopsy bucket."
    },
    {
      "s": "Physical examination",
      "t": "DRE: Normal. The prostate exhibits a symmetrically enlarged, smooth, and firm consistency without palpable nodules or asymmetry. General examination reveals a well-nourished, alert gentleman in no acute distress. Blood pressure measures 138/89 mmHg, accompanied by a regular heart rate of 85 bpm."
    }
  ],
  "occupation": "retired carpenter",
  "marital": "Widowed",
  "living": "Lives in retirement community (independent unit)",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Cardiology — annual review (stable, autumn 2024)"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Swimming 1x/week",
  "ipss": "IPSS score: 9/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "OLVG (Amsterdam)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b63dfe0f311e
Task: 1

Encounter: Urology - outpatient on 17 Feb 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 5.3 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.1 ng/mL²
  - PSA velocity: 0.47 ng/mL/yr
  - Prior PSA: 5.1 ng/mL
  - Prostate volume: 50.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.39097 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 5.3 ng/mL. PI-RADS 2. PSAD 0.10. Prostate volume 50 mL. csPCa 0.39.

Vitals: weight 68 kg, height 175 cm, BMI 22.2, BP 138/89 mmHg, HR 85 bpm. Smoking: Ex-smoker (37 pack-yr, quit 2018).

Chief complaint: Ongoing evaluation of elevated prostate-specific antigen levels alongside reassessment after a previous biopsy.

History: First noted for a PSA rise in late 2022, this 67-year-old widower has since been tracked by his primary care physician. He works as a retired carpenter residing in an independent retirement community, with his sister designated as next of kin. A 37 pack-year smoking history ends in 2018. Clinical background includes hypertension and hypercholesterolaemia, currently treated with amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, and rosuvastatin. He avoids alcohol entirely, swims weekly, and manages mild knee pain stemming from years of manual labour. A cardiology assessment in autumn 2024 confirmed stable cardiovascular health. Urinary symptoms remain minimal, anchored at a baseline IPSS of 9, and he commutes 60 minutes by train for each clinic visit. The clinical picture aligns with a positive prior biopsy bucket.

Physical examination: DRE: Normal. The prostate exhibits a symmetrically enlarged, smooth, and firm consistency without palpable nodules or asymmetry. General examination reveals a well-nourished, alert gentleman in no acute distress. Blood pressure measures 138/89 mmHg, accompanied by a regular heart rate of 85 bpm.

Patient info: retired carpenter; Widowed; Lives in retirement community (independent unit).
Next of kin: Sibling (sister).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Swimming 1x/week; IPSS score: 9/35 (moderate LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024).
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.25
  uncertainty  +/- 0.10 epistemic (95% band 0.05-0.45); among patients I cannot tell apart the outcome was 0.81 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 2 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 67 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 5.3 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 50 mL (1% of my signal; from log_vol, vol) · PSA density = 0.1 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.39 (1% of my signal; from cspca) · PI-RADS = 2 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PI-RADS 1-2 on the current mpMRI: there is no lesion to sample. In the labelled series this criterion matched the reading urologist in 2 of 2 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PI-RADS = 2
  important  prior biopsy = Positive
  noted      age = 67 · DRE = Normal · PSA = 5.3 ng/mL · prostate volume = 50 mL · PSA density = 0.1 · comorbidity = 2 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: clear — the rule matched the reading urologist in 2 of 2 labelled cases

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.81: PI-RADS 2, PSA 4.7, PSAD 0.14, age 67, DRE Normal -> DEFER (clear). He wrote: "Priads 2 with only sightly elevated PSA"
  2. distance 2.03: PI-RADS 3, PSA 7.7, PSAD 0.11, age 64, DRE Normal -> DEFER (borderline). He wrote: "Low risk PC with PSA <10. No red flags on biopsy or MRI, reasonably low PSA density. MRI finding minor and probably penetrated by systematic biopsy core (peripheral zone…"
  3. distance 2.03: PI-RADS 2, PSA 8.3, PSAD 0.206, age 66, DRE Nodus -> DEFER (clear). He wrote: "Patient with low-risk cancer on active surveillance. Now normal MRI."

PRECEDENT: DEFER (weighted vote 0.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  decisive   PI-RADS = 2
  important  PSA = 5.3 ng/mL
  noted      family history = not opened (0 of 91) · age = 67 · DRE = Normal · prostate volume = 50 mL · PSA density = 0.1 · comorbidity = 2 on the problem list
  not used   prior biopsy, csPCa probability
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Positive · age = 67 · PSA = 5.3 ng/mL · PI-RADS = 2
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 50 mL · PSA density = 0.1 · comorbidity = 2 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines address the use of MRI for prostate cancer diagnosis and the role of biopsy. "A stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable low PSA-D < 0.15." This suggests that a stable MRI with a low PSA density might exclude the need for a biopsy.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I note that the guideline treats PSA density as a factor in excluding biopsy, whereas EXPERT-STRUCTURED marked PSA density as not used. The guideline suggests that a stable low PSA-D < 0.15ng/mL/cc might exclude biopsy, which contrasts with EXPERT-STRUCTURED's assessment. The guideline requires a comparison MRI to assess stability, which is not represented by any panel variable.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: at Positive the guideline implies a need to assess the current situation against the guideline's criteria for repeat sampling; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: the guideline implies that a stable PSA trend is relevant, which is not explicitly captured by the current PSA value alone; if it is unrecorded the indication stands
laboratory_results - the PSA density: the guideline makes decisive here, as the threshold of 0.15ng/mL/cc is a key factor in risk stratification.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges on whether the stable PI-RADS 2 finding and low PSA density, as suggested by the EAU guideline, are sufficient to defer biopsy despite the positive prior biopsy.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Must state whether the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Must describe the PSA velocity to assess stability.
  previous_notes (get_previous_notes) -> Must detail the prior biopsy status, including the grade (Gleason/ISUP), number of sessions, and surveillance plan.
  laboratory_results (get_lab_results) -> Must provide the PSA density value to assess against the EAU threshold of 0.15 ng/mL/cc.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What must the radiology_report answer regarding whether the lesion is compared against an earlier study?
  Q2. What must the psa_trend answer regarding the PSA velocity, as the guideline implies a stable trend is relevant?
  Q3. What must the laboratory_results answer regarding the PSA density, as the EAU guideline makes this decisive?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
OLVG Amsterdam | 10 February 2025 | Multiparametric MRI of the Prostate. The lesion is compared against an earlier study: new. LESION: The gland occupies approximately 50.0 mL. T2 sequences highlight a uniform peripheral zone, entirely free of focal hypointense abnormalities.
psa_trend
The PSA velocity is rising, with values from "Oct 2022" at "0.9", "Dec 2023" at "1.7", and "Feb 2025" at "5.3".
previous_notes
PRIOR GRADE: Gleason 3+3 disease. BIOPSY SESSIONS: not recorded. SURVEILLANCE: directed to the urology outpatient clinic for further assessment. TREATMENT: none recorded.
laboratory_results
The PSA density value is "0.1 ng/mL/mL".

WHAT I DID NOT OPEN
family-history anamnesis, because it was not required to answer the specific questions posed by the moderator.

WHAT THIS SUPPORTS
FOR sampling this patient now
The previous notes state the prior biopsy confirmed Gleason 3+3 disease.
The laboratory results show a PSA density of "0.1 ng/mL/mL", which is below the EAU threshold of 0.15 ng/mL/cc.
AGAINST sampling this patient now
The mpMRI report shows a PI-RADS score of "2", which is low risk.

WHERE THIS LEANS
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 5.30 ng/mL over 3 points spanning 28 months; velocity +1.89 ng/mL per year; doubling time about 11 months.
PROJECTION at 6 months: 7.2 ng/mL, conformal 95% band 2.1-25.2.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 5.3 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.21
  uncertainty  +/- 0.09 epistemic (95% band 0.03-0.38), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 86% of the time over the 36 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 2 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      DRE = Normal (5% of my signal; from dre_suspicious) · PSA = 5.3 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 50 mL (4% of my signal; from log_vol, vol) · PSA density = 0.1 (0% of my signal; from psad_calc) · comorbidity = 2 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, csPCa probability
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 86% of the time over the 36 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.25  ('firm' tier; weight 3.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.21  ('firm' tier, fusion_full; weight 4.5)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.00  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule pirads_le_2; does not vote)

  documented prior grade in the opened documents: GG 1 ("Gleason 3+3")

RULE THAT FIRED: cohort criterion (pirads_le_2) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 2 of 2 labelled cases in exactly this situation (prior positive biopsy).

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:— E2:—              -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          67                           E1:not E3:— cohort:not library:not E2:—              -> important
  dre          Normal                       E1:not E3:not cohort:not library:not E2:—            -> noted
  psa          5.3 ng/mL                    E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          50 mL                        E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.1                          E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.39                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       2                            E1:not E3:IMP cohort:DEC library:DEC E2:—            -> important
  comorbidity  2 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened appear to answer the moderator's questions. The `radiology_report` states the lesion is compared against an earlier study ("new"). The `psa_trend` describes the rising PSA velocity, and the `laboratory_results` provide the PSA density value.

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of NO BIOPSY. Specifically, the `laboratory_results` showing a PSA density of "0.1 ng/mL/mL" supports the guideline-based reasoning that might exclude biopsy.

THE OPEN QUESTIONS, ONE BY ONE
Q1. The `radiology_report` answers this by stating the lesion is compared against an earlier study: new.
Q2. The `psa_trend` answers this by describing the PSA velocity as rising, with values from "Oct 2022" at "0.9", "Dec 2023" at "1.7", and "Feb 2025" at "5.3".
Q3. The `laboratory_results` answers this by providing the PSA density value of "0.1 ng/mL/mL", which is below the EAU threshold of 0.15 ng/mL/cc.

WHAT CARRIES WEIGHT, AND WHY
<pirads>: 2: important because EXPERT-COHORT marked it decisive, matching the rule that fired in the PANEL-PROTOCOL. I would not move this level.
<psad>: 0.1: noted because the laboratory result is below the EAU threshold of 0.15 ng/mL/cc, which is a key factor in the guideline. I agree with the PANEL-PROTOCOL's level.
<prior biopsy>: Positive: important because this variable was decisive for multiple experts and the cohort criterion. I agree with the PANEL-PROTOCOL's level.
My confidence in the record as it stands is clear because all required documents were retrieved and answered the moderator's questions.

MY SUGGESTION TO THE CHAIR
I suggest deferral, as the retrieved data, particularly the low PSA density and PI-RADS 2, aligns with the EAU guideline's criteria for excluding biopsy, despite the rising PSA trend.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

67y male, PSA 5.3, PSAD 0.1, PI-RADS 2, prior positive biopsy (Gleason 3+3). Low PSAD and PI-RADS 2 suggest no targetable lesion on current MRI. Given prior diagnosis and low-risk features, defer biopsy and follow PSA trend, re-image if rise.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
